Skip to main content

Table 1 Osteoprotegerin genotype frequencies in prostate cancer patients (PCa) and control males

From: A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer

149 T/C
   149 T/C Genotype C allele frequency (%)
Study group Total no. CC TC TT  
PCaa 361 4 (1.1) 84 (23.3) 273 (75.6) 12.742
   Stageb      
   A 24 1 (4.2) 5 (20.8) 18 (75.0) 14.583
   B 184 1 (0.5) 40 (21.7) 143 (77.8) 11.413
   C 56 1 (1.8) 16 (28.6) 39 (69.6) 16.071
   D 97 1 (1.0) 23 (23.7) 73 (75.3) 12.886
   Organ confined PCa 208 2 (1.0) 45 (21.6) 161 (77.4) 11.778
   Extraprostatic PCa 153 2 (1.3) 39 (25.5) 112 (73.2) 14.052
   Localized Pca 264 3 (1.1) 61 (23.1) 200 (75.8) 12.689
   Metastatic Pca 97 1 (1.0) 23 (23.7) 73 (75.3) 12.887
Gradec      
   Low/Intermediate 257 1 (0.4) 55 (21.4) 201 (78.2) 11.089
   High 104 3 (2.9) 29 (27.9) 72 (69.2) 16.826
Control 195 3 (1.5) 37 (19.0) 155 (79.5) 11.026
950 T/C
   950 T/C Genotype (%) C allele frequency (%)
Study group Total no. CC TC TT  
PCaa 361 63 (17.4) 162 (44.9) 136 (37.7) 39.889
   Stageb      
   A 24 8 (33.3) 8 (33.3) 8 (33.3) 50
   B 184 36 (19.6) 84 (45.6) 64 (34.8) 42.391
   C 56 9 (16.0) 30 (53.6) 17 (30.4) 42.857
   D 97 11 (10.3) 39 (41.2) 47 (48.5) 30.927
   Organ confined PCa 208 44 (21.2) 92 (44.2) 72 (34.6) 43.269
   Extraprostatic PCa 153 19 (12.4) 70 (45.8) 64 (41.8) 35.294
   Localized Pca 264 53 (20.0) 122 (46.3) 89 (33.7) 43.181
   Metastatic Pca 97 11 (10.4) 39 (41.2) 47 (48.4) 30.927
Gradec      
   Low/Intermediate 257 48 (18.7) 116 (45.1) 93 (36.2) 41.245
   High 104 15 (14.4) 46 (44.3) 43 (41.3) 36.538
Control 195 29 (14.9) 98 (50.2) 68 (34.9) 40
  1. a Prostate cancer versus control, P = 0.939 and 0.294 by the chi-square test for 149 T/C and 950 T/C, respectively.
  2. b According to the Whitmore-Jewett system. Stage A = T1a-bN0M0, Stage B = T1c-2N0M0, Stage C = T3–4N0M0 and Stage D = T1–4N1M0–1 or T1–4N0–1M1. Localized PCa (Stage A + B + C) versus Metastatic PCa (Stage D) P = 0.931 and 0.005 by the chi-square test for 149 T/C and 950T/C, respectively. Organ confined (Stage A + B) versus Extraprostatic PCa (Stage C + D), P = 0.346 and 0.021 by the chi-square test for 149 T/C and 950T/C, respectively.
  3. c Low grade = well-differentiated carcinoma (WHO) or Gleason score 2–4 carcinoma, Intermediate grade = moderately differentiated carcinoma (WHO) or Gleason score 5–7 carcinoma, High grade = poorly differentiated carcinoma (WHO) or Gleason score 8–10 carcinoma. C allele frequency, P = 0.884 and 0.520 by the chi-square test for 149 T/C and 950 T/C, respectively.
\